Loading...

HealthLynked Corp.

HLYKPNK
Healthcare
Medical - Care Facilities
$2.50
$-0.35(-12.28%)
U.S. Market is Open • 11:47

HealthLynked Corp. Fundamental Analysis

HealthLynked Corp. (HLYK) shows moderate financial fundamentals with a PE ratio of -2.17, profit margin of -1.59%, and ROE of 65.33%. The company generates $0.0B in annual revenue with weak year-over-year growth of -47.43%.

Key Strengths

ROE65.33%
PEG Ratio-0.03

Areas of Concern

Operating Margin-1.02%
Cash Position0.52%
Current Ratio0.22
We analyze HLYK's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -116.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-116.7/100

We analyze HLYK's fundamental strength across five key dimensions:

Efficiency Score

Weak

HLYK struggles to generate sufficient returns from assets.

ROA > 10%
-1.93%

Valuation Score

Excellent

HLYK trades at attractive valuation levels.

PE < 25
-2.17
PEG Ratio < 2
-0.03

Growth Score

Weak

HLYK faces weak or negative growth trends.

Revenue Growth > 5%
-47.43%
EPS Growth > 10%
-4.59%

Financial Health Score

Moderate

HLYK shows balanced financial health with some risks.

Debt/Equity < 1
-1.01
Current Ratio > 1
0.22

Profitability Score

Weak

HLYK struggles to sustain strong margins.

ROE > 15%
65.33%
Net Margin ≥ 15%
-1.59%
Positive Free Cash Flow
No

Key Financial Metrics

Is HLYK Expensive or Cheap?

P/E Ratio

HLYK trades at -2.17 times earnings. This suggests potential undervaluation.

-2.17

PEG Ratio

When adjusting for growth, HLYK's PEG of -0.03 indicates potential undervaluation.

-0.03

Price to Book

The market values HealthLynked Corp. at -1.23 times its book value. This may indicate undervaluation.

-1.23

EV/EBITDA

Enterprise value stands at -0.74 times EBITDA. This is generally considered low.

-0.74

How Well Does HLYK Make Money?

Net Profit Margin

For every $100 in sales, HealthLynked Corp. keeps $-1.59 as profit after all expenses.

-1.59%

Operating Margin

Core operations generate -1.02 in profit for every $100 in revenue, before interest and taxes.

-1.02%

ROE

Management delivers $65.33 in profit for every $100 of shareholder equity.

65.33%

ROA

HealthLynked Corp. generates $-1.93 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.93%

Following the Money - Real Cash Generation

Operating Cash Flow

HealthLynked Corp. generates limited operating cash flow of $-2.67M, signaling weaker underlying cash strength.

$-2.67M

Free Cash Flow

HealthLynked Corp. generates weak or negative free cash flow of $-2.67M, restricting financial flexibility.

$-2.67M

FCF Per Share

Each share generates $-0.91 in free cash annually.

$-0.91

FCF Yield

HLYK converts -34.95% of its market value into free cash.

-34.95%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.17

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.03

vs 25 benchmark

P/B Ratio

Price to book value ratio

-1.23

vs 25 benchmark

P/S Ratio

Price to sales ratio

3.57

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-1.01

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.22

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.65

vs 25 benchmark

ROA

Return on assets percentage

-1.93

vs 25 benchmark

ROCE

Return on capital employed

0.40

vs 25 benchmark

How HLYK Stacks Against Its Sector Peers

MetricHLYK ValueSector AveragePerformance
P/E Ratio-2.1729.43 Better (Cheaper)
ROE65.33%684.00% Weak
Net Margin-158.83%-45067.00% (disorted) Weak
Debt/Equity-1.010.43 Strong (Low Leverage)
Current Ratio0.224.07 Weak Liquidity
ROA-192.69%-17158.00% (disorted) Weak

HLYK outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews HealthLynked Corp.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-73.66%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

84.94%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

47.97%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ